Dupixent (dupilumab) has been approved by the FDA for use in children with eosinophilic esophagitis.

Published Date: 31 Jan 2024

The US. s. The Food and Drug Administration has given Regeneron's Dupixent (dupilumab) approval to treat pediatric patients with eosinophilic esophagitis (EoE) who are between the ages of one and eleven.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot